SIETES :: 93212 citas

Resultados de la búsqueda por EXCIPIENTES REFINAR BÚSQUEDA

1.

Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2021;384:18 de febrero. [Ref.ID 103836]

2.

Regalado A. What are the ingredients of Pfizer’s covid-19 vaccine?. Nature Briefing 2020:9 de diciembre. [Ref.ID 103832]

3.

Matta MK, Zusterzeel R, Pilli NR, Patel V, Volpe DA, Florian J, Oh L, Bashaw E, Zineh I, Sanabria C, Kemp S, Godfrey A, Adah S, Coelho S, Wang J, Furlong L-A, Ganley C, Michele T, Strauss DG. Effect of sunscreen application under maximal use conditions on plasma concentration of sunscreen active ingredients. A randomized clinical trial. JAMA 2019:6 de mayo. [Ref.ID 103109]

4.

Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ 2018;360:k714. [Ref.ID 102544]

5.

Anónimo. Propylène glycol: un excipient aux effets indésirables dose-dépendants. Prescrire 2017;37:107-8. [Ref.ID 101444]

6.

Anónimo. Medicines, excipients and dietary intolerances. Drug Ther Bull 2016;54:93-6. [Ref.ID 100651]

7.

Anónimo. Implications of religious and cultural beliefs on selection of medicines. Drug Ther Bull 2016;54:45-8. [Ref.ID 100172]

8.

Anónimo. Drugs past their expiration date. Med Lett Drugs Ther 2015;57:164-5. [Ref.ID 99690]

9.

Anónimo. Dabigatran: ulcérations digestives. Prescrire 2014;34:197. [Ref.ID 97364]

10.

Anónimo. Atteintes de la cornée d'origine médicamenteuse. Prescrire 2013;33:908-13. [Ref.ID 96721]

11.

Anónimo. Collyres aux phosphates: opacités cornéennes. Prescrire 2013;33:268. [Ref.ID 95339]

12.

Anónimo. Lopinavir + ritonavir buvable: formulation dangereuse pour les nouveau-nés (suite). Prescrire 2011;31:429. [Ref.ID 91050]

13.

Kuehn BM. Frances Kelsey honored for FDA legacy. Award notes her work on thalidomide, clinical trials. JAMA 2010;304:2109-10. [Ref.ID 89664]

14.

Canfell K. Monitoring HPV vaccination programmes. BMJ 2010;340:667-8. [Ref.ID 88183]

15.

Solà R, Boj M, Hernández-Flix S, Camprubí M. Silica in oral drugs as a possible sarcoidosis-inducing antigen. Lancet 2009;373:1943. [Ref.ID 87466]

16.

Zhu FC, Wang H, Fang H-H, Yang JG, Lin XJ, Liang X-F, Zhang XF, Pan X, Meng F-Y, Hu YM, Liu W-D, Li C-G, Li W, Zhang X, Hu JM, Peng WB, Yang BP, Xi P, Wang HQ, Zheng JS. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361:2414-23. [Ref.ID 87279]

17.

McKinnon RA, Lu CY. Biosimilars are not (bio)generics. Australian Prescriber 2009;32:146-7. [Ref.ID 87186]

18.

Bhakdi S, Lackner K, Doerr H-W. Possible hidden hazards of mass vaccination against new influenza A/H1N1: have the cardiovascular risks been adequately weighed?. Medical Microbiology and Immunology 2009;198:205-9. [Ref.ID 87073]

19.

Anónimo. Insuffisances rénales d'origine médicamenteuse. Prescrire 2009;29:506-10. [Ref.ID 86213]

20.

Anónimo. What are excipients doing in medicinal products?. Drug Ther Bull 2009;47:81-4. [Ref.ID 86136]